Поиск по репозиторию
Статья
Atezolizumab plus bevacizumab in unresectable hepatocellular carcinoma
2020
BACKGROUND The combination of atezolizumab and bevacizumab showed encouraging antitumor activity and safety in a phase 1b trial involving patients with unresectable hepatocellular carcinoma. METHODS In a global, openlabel, phase 3 trial, patients with unresectable hepatocellular carcinoma who had not previously received systemic treatment were randomly assigned in a 2:1 ratio to receive either atezolizumab plus bevacizumab or sorafenib until unacceptable toxic effects occurred or there was a loss of clinical benefit. The coprimary end points were overall survival and progressionfree survival in the intentiontotreat population, as assessed at an independent review facility according to Response Evaluation Criteria in Solid Tumors, version 1.1 (RECIST 1.1). RESULTS The intentiontotreat population included 336 patients in the atezolizumab–bevacizumab group and 165 patients in the sorafenib group. At the time of the primary analysis (August 29, 2019), the hazard ratio for death with atezolizumab–bevacizumab as compared with sorafenib was 0.58 (95% confidence interval [CI], 0.42 to 0.79; P
Цитирование
Похожие публикации
Версии
- 1. Version of Record от 2020-05-14
Метаданные
Название журнала
- New England Journal of Medicine
Том
- 382
Выпуск
- 20
Страницы
- 1894-1905
Финансирующая организация
- F. Hoffmann-La Roche
Номер гранта
- undefined
Тип документа
- journal article
Тип лицензии Creative Commons
- CC BY
Правовой статус документа
- Свободная лицензия
Источник
- scopus
